Apellis Pharmaceuticals, Inc.
- APLS
- NASDAQ
- Biotechnology
- Complement-Targeted Therapies
- Autoimmune/Inflammatory Drugs
$41.03
Quote May 15, 2026, 08:00 PM UTC
+0.39%over the last month
Max drawdown −0.3%From 1-month high −0.2%3 months +89.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$5.25B
Quote May 15
Next earnings
—
Data unavailable
Analyst target
$83.00
+102.3% from here
Floor
$40.53
1.2% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about APLSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q1 2026 revenue $268.3M
- Product$192.0M71.6%
- Licensing And Other Revenue$76.3M28.4%
Industry
Biotechnology
Employees
705